Prospects of induced pluripotent stem cell technology in regenerative medicine.
Prospects of induced pluripotent stem cell technology in regenerative medicine.
复制标题
DOI：
10.1089/ten.teb.2010.0549
复制
发表时间：
2011-02
期刊：
影响因子：
--
通讯作者：
Feng Zhang;Fudiman Citra;Dongan Wang
中科院分区：
文献类型：
--
作者：
Feng Zhang;Fudiman Citra;Dongan Wang
诱导多能干（iPS）细胞源自成体体细胞，通过异位表达四种转录因子（Oct3/4、Sox2、c-Myc 和 Klf4；或 Oct3/4、Sox2、Nanog 和 Lin28）进行重编程，所得细胞重新获得多能性，即某些胚胎细胞独有的在适当条件下分化成任何细胞谱系的能力。鉴于细胞来源的便利性和道德对抗性的放弃，iPS 细胞在药物发现和再生医学的实践中优于胚胎多能细胞。通过再生医学的离体实践，传统药物剂量中涉及的许多问题，例如免疫排斥，都可能得到避免。在本文中，我们简要总结了iPS相关应用的基本原理和现状，并强调了iPS技术在再生医学中的前景。
Induced pluripotent stem (iPS) cells are derived from adult somatic cells via reprogramming with ectopic expression of four transcription factors (Oct3/4, Sox2, c-Myc and Klf4; or, Oct3/4, Sox2, Nanog, and Lin28), by which the resultant cells regain pluripotency, namely, the capability exclusively possessed by some embryonic cells to differentiate into any cell lineage under proper conditions. Given the ease in cell sourcing and a waiver of ethical opponency, iPS cells excel embryonic pluripotent cells in the practice of drug discovery and regenerative medicine. With an ex vivo practice in regenerative medicine, many problems involved in conventional medicine dosing, such as immune rejection, could be potentially circumvented. In this article, we briefly summarize the fundamentals and status quo of iPS-related applications, and emphasize the prospects of iPS technology in regenerative medicine.